Cut-Off Analysis of CTC Change under Systemic Therapy for Defining Early Therapy Response in Metastatic Breast Cancer
Authors:
- Thomas M. DeutschTDThomas M. Deutsch
- Stefan StefanovicSSStefan Stefanovic
- Manuel FeisstMFManuel Feisst
- Chiara FischerCFChiara Fischer
- Fabian RiedelFabian Riedel
- Carlo FremdCFCarlo Fremd
- Christoph DomschkeCDChristoph Domschke
- Klaus PantelKPKlaus Pantel
- Andreas D. HartkopfAHAndreas D. Hartkopf
- Marc SutterlinMSMarc Sutterlin
- Sara Y. BruckerSBSara Y. Brucker
- Andreas SchneeweissASAndreas Schneeweiss
Open Access
Abstract
Detection of circulating tumor cells (CTC) can distinguish between aggressive and indolent metastatic disease in breast cancer patients and is thus considered an independent, negative prognostic factor. A clear decline in CTCs is observed in patients who respond to systemic therapy. Nevertheless, CTCs can decrease in patients experiencing disease progression during systemic therapy, too. This study aims to determine the differences between CTC decline in patients responding to therapy and those in whom disease is progressing. Therefore, CTC values were compared at the start and after one cycle of a new line of systemic therapy. In all, 108 initially CTC-positive patients (with ≥5 intact CTCs in 7.5 mL blood) were enrolled in this study and intact and apoptotic CTCs were measured via the CellSearch® system. A cut-off analysis was performed using Youden’s J statistics to differentiate between CTC change in the two groups. Here, 64 (59.3%) patients showed stable disease or partial response vs. 44 (40.7%) presenting disease progression. Median overall survival was 23 (range: 4–92) vs. 7 (2–43) months (p < 0.001). Median intact CTC count at enrollment was 15.0 (5–2760) vs. 30.5 (5–200000) cells (p = 0.39) and 2.5 (0–420) vs. 8.5 (0–15000) cells after one cycle of systemic therapy (p = 0.001). Median apoptotic CTC count at enrollment was 10.5 (0–1500) vs. 9 (0–800) cells (p = 0.475) and 1 (0–200) vs. 3 (0–250) cells after one cycle of systemic therapy (p = 0.01). A 50% reduction in baseline apoptotic CTC count represents the optimal cut-off to differentiate between therapy response and disease progression. An apoptotic CTC reduction of ≤10% is 74% specific for early disease progression.Keywords
Funding Information
- DISSECT (ERC-2010-AdG_20100317)
This publication has 45 references indexed in Scilit:
- The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancerBreast Cancer Research and Treatment, 2012
- Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast CancerMolecular Cancer Therapeutics, 2012
- Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapyAnnals of Oncology, 2011
- Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentBreast Cancer Research, 2011
- Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patientsBreast Cancer Research, 2011
- High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patientsAnnals of Oncology, 2011
- Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cellsBreast Cancer Research, 2009
- Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall SurvivalClinical Cancer Research, 2006
- Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast CancerNew England Journal of Medicine, 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000